How Providers Can Lead the Ozempic Face Conversation in 2026: A Strategic Guide for Telehealth Platforms, Medspas, and Aesthetic Practices

An operator's guide to the fastest-emerging patient concern in GLP-1 care, and what your practice should do about it.

If you run a GLP-1 telehealth platform, an aesthetic medicine practice, a medspa, or a menopause/hormone provider, your patients are bringing up "Ozempic face" already. The question is no longer whether the conversation is happening. It's whether your practice is leading it or reacting to it.

This guide covers what every provider needs to know about Ozempic face in 2026: the published research, the patient experience, the failed market response, the operational considerations for adding skin support to GLP-1 care, and what to look for in a clinical skincare partner.

PowerV, a skin longevity serum formulated specifically around the visible concerns GLP-1 patients raise, is referenced throughout this guide as one example of how a clinically-credentialed skincare partner can fit into a GLP-1 provider's care pathway. PowerV is one of several brands in this emerging category, included here because of its specific formulation alignment with the published research discussed below.

We'll cover:

• The market size and patient demand
• What the 2025 Vanderbilt study established
• The three responses providers are giving (and which one is the standard of care)
• Why most "Ozempic face" products are failing patients
• What to look for in a clinical skincare partner
• Operational models for integrating skincare into GLP-1 care
• How PowerV partnerships work

The Market Reality: Why This Conversation Matters Now

GLP-1 medication adoption is the fastest pharmaceutical expansion in modern history. JP Morgan analyst forecasts project approximately 15 million Americans on GLP-1 medications by the end of 2025, growing to 30 million by 2030. That's nearly 1 in 10 American adults.

For providers, this represents both an opportunity and a risk.

The opportunity. Patients on GLP-1s are highly engaged with their care. They're on a daily or weekly medication routine. They're tracking weight, body composition, and increasingly, their appearance. They're actively researching adjuncts to their treatment. The patient who's been on Ozempic for six months is a fundamentally different consumer than the patient who walked in cold. They want comprehensive care.

The risk. Patients are noticing facial appearance changes during treatment, and most providers don't have a credible answer when asked. Patients are spending money on skincare products that don't deliver. Some are reducing their GLP-1 dose or pausing treatment because of skin and facial concerns. The "I don't recognize my face" conversation is happening with or without you.

Practices that fold skin support into their GLP-1 protocols are seeing measurable improvements in patient satisfaction, retention, and clinical outcomes. Brands like PowerV have emerged specifically to fill the gap between generic anti-aging skincare and the actual visible concerns GLP-1 patients raise. Practices that integrate one of these specialized solutions are seeing better engagement metrics than those that don't address the concern at all.

The 2025 Vanderbilt Study: What Was Established

In August 2025, Otolaryngology Head and Neck Surgery published the first objective imaging quantification of GLP-1 facial volume changes.

Citation: Sharma RK, Vittetoe KL, Barna AJ, Takkouche S, Varelas AN, Yang SF, Stephan SJ, Patel PN. "Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists." Otolaryngology Head and Neck Surgery. 2025 Aug;173(2):360-366. DOI: 10.1002/ohn.1209. PMID: 40407186.

The Vanderbilt facial plastic surgery team analyzed 20 patients with CT and MRI imaging before and after GLP-1 prescriptions. Median patient age 54. Average GLP-1 therapy duration 321 days. Average weight loss 11.0 kg.

Findings:

• 9% median decrease in total midfacial volume (interquartile range 3-14%)
• 11% median decrease in superficial fat compartment volume (the layer most associated with facial firmness)
• 7% median decrease in deep fat compartment volume, with wide patient variability
• Linear regression: approximately 7% facial volume loss per 10 kg of weight lost

The losses concentrated in superficial fat compartments. This is the layer that contributes most visibly to facial firmness and youthful contour.

The study is small (n=20) and represents the first peer-reviewed imaging quantification of a phenomenon facial plastic surgeons have been observing clinically since 2022. For providers, the takeaway is that the appearance changes patients describe are now objectively documented, not anecdotal.

A 2025 review published in Endocrine (Paschou et al., "GLP-1 receptor agonists and possible skin aging," 2025;89:680-685) further discussed emerging hypotheses about GLP-1 receptors in skin cells, suggesting the mechanism of facial appearance change may extend beyond fat loss alone. This research remains hypothesis-stage but is increasingly cited in aesthetic medicine literature.

PowerV's formulation was specifically built around ingredients with published research relevant to these findings: actives studied for their support of skin firmness, density appearance, and barrier resilience during periods of physiological change.

The Three Responses Providers Are Giving

Based on patient reports and industry observation, GLP-1 providers are responding to skin and appearance concerns in three distinct ways. Only one represents the emerging standard of care.

Response 1: The dismissive response. "That's just part of weight loss. Your face will adjust."

This response misses several things. The Vanderbilt data confirms that GLP-1 facial volume change has specific, measurable characteristics that differ from normal weight loss. The concern is not vanity. And dismissing it damages patient trust in the entire treatment relationship.

Response 2: The redirect response. "You might want to see a dermatologist or plastic surgeon."

This response is appropriate when patients have significant volume loss that may warrant filler, Sculptra, fat transfer, or surgical consultation. But it's not always the right starting point. For patients with mild to moderate visible concerns, redirecting to a specialty consult feels dismissive and adds friction to the journey. Some patients won't follow up.

Response 3: The integrated response. "Let's talk about what you're noticing and what might help, from topical support to more involved options if needed."

This is the emerging standard of care. The provider validates the concern, offers a science-credentialed topical recommendation like PowerV as a first step, and references more involved options if the topical support isn't sufficient. The patient feels heard and has a concrete next step that fits the rhythm of their ongoing treatment.

The practices doing Response 3 are folding skincare into their care pathways at predictable touchpoints: onboarding, the first 90 days, and the GLP-1 success programs. They're seeing better retention and stronger member experience scores as a result.

Why Most "Ozempic Face" Skincare Products Are Failing Patients

The skincare industry has responded to Ozempic face the way it responds to every new beauty conversation: by relabeling existing products.

Walk into any beauty retailer in 2026 and you'll see "Ozempic face creams," "weight loss recovery serums," and "GLP-1 skin solutions" from brands that were marketing the same product as anti-aging six months ago. The formulations haven't changed. The marketing has.

Here's what's actually missing from most of these launches: published clinical research relevant to the specific visible concerns GLP-1 patients are raising.

Standard anti-aging serums focus on the surface of the skin. Retinol, vitamin C, glycolic acid, generic peptides. These ingredients have decades of research supporting their role in normal aging. But the visible concerns GLP-1 patients raise (firmness, density, resilience, barrier function) involve different skin biology than surface-level actives address.

The result for patients: they try these products, see no meaningful change, lose trust in whoever recommended them, and either stop using skincare entirely or go searching elsewhere.

This is the gap PowerV was built to fill. Rather than repackaging an existing anti-aging serum, PowerV is formulated around two Mibelle Biochemistry actives with published clinical research specifically relevant to the visible concerns GLP-1 patients describe. The brand's positioning is built on this distinction.

The result for providers who recommend the wrong products: the patient who was on the verge of becoming a high-LTV repeat customer disengages. They show up to the next appointment less satisfied, more skeptical of provider recommendations in general, and more likely to churn from the practice.

The downstream impact on practice economics is real. Retention is the single biggest lever in GLP-1 telehealth and aesthetic medicine. A skincare recommendation that fails the patient costs you more than the patient pays for the product.

What to Look For in a Clinical Skincare Partner

If your practice is considering folding skincare into your GLP-1 care pathway, here's what separates a credible partner from another marketing-driven launch.

1. Ingredient research over product marketing.

Ask the brand: what published clinical research backs the key ingredients in your product, and at what concentrations? Look for ingredients with peer-reviewed in-vivo human research relevant to the specific visible concerns patients are raising. Avoid brands that lead with vague "clinically tested" claims without specifying what was tested.

For reference, PowerV is built around PhytoCellTec Argan (Mibelle Biochemistry research has shown a 12.7% improvement in skin density measurements over 56 days and a 13.1% reduction in nasolabial fold appearance over 84 days in a placebo-controlled, half-face study at studied concentrations) and MossCellTec No. 1 (Mibelle research has shown an 8% improvement in skin barrier function over 28 days). These are examples of the kind of substantiation a credible clinical partner should be able to provide.

2. Finished-product safety substantiation.

The ingredient research is necessary but not sufficient. Ask: has your finished product been independently safety-tested? The standard is an HRIPT (Human Repeat Insult Patch Test) with 50+ subjects, GCP-compliant, signed off by a board-certified dermatologist. This is the minimum bar for credibility in clinical channels.

PowerV itself was independently safety-tested in a 52-subject HRIPT clinical panel, GCP-compliant, signed by a board-certified dermatologist, with zero adverse events.

3. MoCRA compliance and FDA-registered manufacturing.

Under the Modernization of Cosmetics Regulation Act (MoCRA), cosmetic products marketed in the US must meet specific safety substantiation, labeling, and registration requirements. Ask: are you MoCRA compliant? Is your manufacturer FDA-registered? Can you provide a Certificate of Analysis per production lot?

PowerV is manufactured at an FDA-registered facility (BL Bio Lab, Clearwater, Florida), with full CoA provided per production lot.

4. Honest positioning about what skincare can and cannot do.

Be wary of brands claiming to "fix" or "treat" Ozempic face. No topical product restores lost facial fat volume at meaningful levels. The credible positioning is that skincare can support visible firmness, density appearance, and barrier resilience, and that for significant volume loss, patients may eventually need filler, Sculptra, or surgical consultation. A partner who overclaims today is a liability tomorrow.

PowerV's own marketing and clinical communications are explicit about this distinction. The brand positions itself as a science-backed topical for visible concerns related to firmness, density, and barrier resilience, not as a replacement for filler or surgical intervention.

5. Operational simplicity for the practice.

The best partnership models for early integration require zero inventory, zero fulfillment, zero customer support burden on the practice. Look for tracked referral arrangements rather than wholesale models if you're just starting to test skin support as an adjunct to your care. Wholesale comes later, once you've validated patient demand.

PowerV's standard partnership model is a tracked referral with no inventory required, which makes it suitable for practices testing the category for the first time.

Operational Models for Integrating Skincare Into GLP-1 Care

Three models are emerging across the GLP-1 provider landscape, with different operational implications.

Model 1: Tracked referral with no inventory.

The practice receives a tracked referral link. Patients click through, purchase directly from the skincare brand, and the practice receives a revenue share on net sales. Zero inventory, fulfillment, support, or regulatory burden on the practice.

Best for: telehealth platforms, smaller medspas, practices testing skincare as a care adjunct for the first time, practices that want to maintain optionality across multiple brand partners.

Typical economics: 15-25% revenue share on retail. Goes live in 1-4 weeks. This is the model PowerV uses as the default partnership entry point.

Model 2: Wholesale retail.

The practice purchases inventory at wholesale, retails to patients at suggested retail, and captures the margin. Requires inventory management, point-of-sale setup, and staff training.

Best for: established medspas with existing retail operations, aesthetic dermatology practices with mature retail counters, practices that want to own the customer relationship.

Typical economics: 40-60% margin on retail. Setup time 4-12 weeks depending on inventory management complexity. PowerV offers wholesale arrangements for established retail operations as a later-stage partnership tier.

Model 3: Co-branded or curated protocols.

The practice and the skincare partner co-develop a protocol or product line specifically for the practice's patient base. May involve some custom formulation, custom packaging, or curated bundles.

Best for: large practices with strong brand identity, telehealth platforms with established member experience programs, longevity clinics with comprehensive care pathways.

Typical economics: variable, often combines wholesale margin with brand licensing fees. Setup time 3-9 months. PowerV considers co-branded arrangements for partners at sufficient scale.

Most practices start with Model 1, validate patient demand and operational fit, then move toward Model 2 or 3 as confidence grows.

What Practices Get Right vs. What They Get Wrong

Patterns we've observed across practices integrating skincare into GLP-1 care:

What's working:

• Folding skincare into onboarding and the first 90 days of treatment, when patients are most engaged
• Training clinicians to validate the visible concerns conversation, not deflect it
• Offering a single, vetted, science-credentialed recommendation rather than overwhelming patients with options (PowerV is often selected for this role because of its specific formulation alignment with GLP-1 visible concerns)
• Building a structured follow-up around skin (90-day check-in, photos, satisfaction scores)
• Integrating the recommendation into the digital member experience (app, portal, email sequence)

What's failing:

• Treating skincare as an afterthought or an upsell at the end of an appointment
• Recommending whatever product the practice has lying around without conviction or context
• Stocking 5+ competing brands and asking patients to choose (decision fatigue kills conversion)
• Failing to follow up on what the patient experienced
• Allowing front-desk staff or non-clinical team members to be the primary educator on a clinical product

The pattern is consistent: skincare integrated thoughtfully into the care journey strengthens the entire practice. Skincare sold opportunistically degrades trust.

A Note on PowerV

PowerV is a skin longevity serum formulated specifically around the visible concerns GLP-1 patients are raising during rapid weight change.

PowerV is built around two Mibelle Biochemistry actives with published clinical research relevant to skin firmness, density, and barrier appearance: PhytoCellTec Argan and MossCellTec No. 1. The formulation includes astaxanthin, ceramide complex, beta-glucan, and squalane. No retinol. Designed for sensitive, reactive skin.

PowerV itself has been independently safety-tested in a 52-subject HRIPT clinical panel, GCP-compliant, signed by a board-certified dermatologist, with zero adverse events. Made in an FDA-registered facility. Full Certificate of Analysis per production lot.

We built PowerV because we couldn't find another serum specifically designed around published research on the visible concerns GLP-1 patients raise, rather than repackaged anti-aging marketing.

PowerV is a cosmetic product and is not intended to diagnose, treat, cure, or prevent any disease.

How PowerV Partnerships Work

PowerV partners with GLP-1 telehealth platforms, menopause and hormone telehealth providers, medspa chains, aesthetic dermatology practices, and longevity clinics through a simple referral model.

Partnership terms:

• Tracked referral link, deployable in 2 weeks
• Zero inventory, fulfillment, or operational burden on the practice
• 20% revenue share on net sales at $79 retail
• 25% at volume tiers (500+ units/month)
• 30-day test runs available

Sample economics at a 3% attach rate across 100K members with 60-day repeat purchase: approximately $4-6M in annual gross revenue through the referral channel, with $800K-$1.2M flowing back to the practice or platform.

Built for scale:

• 8-week manufacturer lead time
• Production capacity for 10K to 100K unit runs
• FDA-registered manufacturing partner
• Full regulatory and compliance posture

Getting Started

If your practice is treating GLP-1 patients and you're ready to fold skin support into your care pathway, here's a practical sequence:

Step 1: Internal alignment. Decide who at your practice owns the skin conversation. Most practices put it under clinical leadership with marketing/member experience support. Avoid making it solely a marketing initiative.

Step 2: Vendor evaluation. Run any potential skincare partner through the five criteria above. Ingredient research, finished-product safety, honest positioning, operational simplicity. PowerV is one option in this category and can be evaluated against the same criteria.

Step 3: Test run. Start with a tracked referral partnership and a 30-day evaluation. Measure: patient adoption rate, repeat purchase rate, NPS impact, clinical team feedback.

Step 4: Scale or pivot. If the test run validates patient demand and operational fit, scale the partnership. If it doesn't, you've spent 30 days and learned a lot.

Step 5: Build the protocol. Once you have a validated skincare partner, integrate it into your care pathway at the right touchpoints. Onboarding, 90-day check-in, GLP-1 success program, retention recovery sequences.

Reach Out

To explore a PowerV partnership for your practice or platform, email team@powervskin.com or reach out via LinkedIn.

We'll send the full data room: clinical studies, HRIPT report, Certificate of Analysis, founder bio, and partnership deck. 15-minute introductory conversations welcome.

The Ozempic face conversation is happening across the GLP-1 provider landscape in 2026. The practices that lead it credibly will define the standard of care for the next decade.

About PowerV

PowerV is a science-backed regenerative skin longevity serum formulated around published clinical research on skin firmness, density, and barrier resilience. Founded by Rasu, PowerV is manufactured at BL Bio Lab in Clearwater, Florida. The brand serves customers through pwoervskin.com, TikTokShop, Amazon, and partners with healthcare and aesthetic providers through a referral partnership program.

For questions and partnerships: team@powervskin.com

The New Skincare by PowerV.
The New Way To Age Gracefully.
FIRM. LIFT. BOUNCE. REGENERATE.

Sources cited:

• Sharma RK et al. "Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists." Otolaryngology Head and Neck Surgery. 2025 Aug;173(2):360-366.
• Paschou IA et al. "GLP-1 receptor agonists and possible skin aging." Endocrine. 2025;89:680-685.
• JP Morgan analyst forecasts on US GLP-1 medication adoption.